News | News By Subject | News by Disease News By Date | Search News

Thrombosis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Exciting Time for Biotech in New Jersey     6/29/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 2 Data For ISIS-FXI Rx For The Prevention Of Venous Thrombosis In Patients Undergoing Total Knee Replacement Surgery     12/8/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
FDA Approves Use Of Bristol-Myers Squibb Company (BMY), Pfizer Inc. (PFE)'s Eliquis To Treat Leg, Lung Clots     8/22/2014
Regado Biosciences, Inc. (RGDO) Shares Nearly Halved After Announcing Trial Review; Stock Down -58.43% At Market Close (July 3, 2014)     7/7/2014
Boehringer Ingelheim Corporation's Investigational Antidote For Pradaxa® Grabs FDA Breakthrough Therapy Designation     6/26/2014
Boehringer Ingelheim Corporation's Pradaxa® Wins EU Approval To Treat Deep Vein Thrombosis And Pulmonary Embolisms     6/6/2014
Bayer AG (BAY.F) to Address FDA's Questions on Xarelto     6/28/2013
GlaxoSmithKline (GSK) Negotiating $1 Billion Sale of Thrombosis Drugs to Aspen Pharmacare Ltd.     6/20/2013
Bayer AG (BAY.F), Johnson & Johnson (JNJ)'s Xarelto Gets FDA Priority Review     7/10/2012
Johnson & Johnson (JNJ) Seeks Further FDA Thrombosis OK for Xarelto     5/10/2012
Johnson & Johnson (JNJ) and Bayer HealthCare (BAY) Seek Added Use for Xarelto     5/3/2012
FDA Issues Import Alerts for 22 Chinese Heparin Suppliers     2/24/2012
Bayer HealthCare (BAY)'s Xarelto┬« (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in Non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis     12/19/2011

News from Around the Web
Artificial Blood Vessels Become Resistant To Thrombosis, ITMO University Study     8/4/2015
Walking Dead: Biotech "Zombie" Companies And Why They Are Failing     10/15/2014
Drug Combo May Be Best for Plaque Regression, University of Calgary Study     5/2/2011
Dalteparin Not Superior to Unfractionated Heparin, McMaster University Study     3/24/2011
Double-Dose Clopidogrel (Plavix) Does Not Reduce Heart Attack or Stent Thrombosis for Angioplasty Patients with High Platelet Reactivity, Scripps Translational Science Institute Study     3/17/2011
Mechanical Clearing of Leg Veins Prevents Deep Vein Thrombosis, A.T. Still University Study     9/27/2010
Fondaparinux Cuts Risks of SVT Leg Thrombosis, Universite Jean-Monnet     9/23/2010
ESC: EINSTEIN DVT Data Positive for Factor Xa Inhibitor, Academic Medical Center Study     9/1/2010
Oral Factor Xa Inhibitor Prevents Postsurgical Thrombosis, McMaster University Study     5/8/2009
Blood Thinning Drug Warfarin Linked To Increased Bleeding In Brain, University of Cincinnati Study     9/30/2008
Statins "Can Help To Prevent Arteries From Aging" -- University of Cambridge Study     9/29/2008
Inhibiting Cholesterol-associated Protein Reduces High-risk Blockages In Arteries, University of Pennsylvania School of Medicine Study     9/29/2008
Migraine Sufferers Prone To Leg Clots, Innsbruck Medical University Study     9/16/2008
Doctors Say Leg Pain Can Signal Deadly Blood Clot     9/15/2008
FDA Finds Unidentified Substance In Baxter International, Inc. (BAX)'s Blood-Thinning Drug Heparin     3/6/2008

Press Releases
China Biologic Products Receives CFDA Clinical Trial Approval For Human Antithrombin III     10/11/2016
Daiichi Sankyo To Present Findings From New Subgroup Analyses Of Once-Daily SAVAYSA (edoxaban) In NVAF And VTE At American College of Cardiology's 65th Annual Scientific Session     3/24/2016
Boehringer Ingelheim Launches RE-COVERY DVT/PE: Global Observational Study On Management Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) With Pradaxa (Dabigatran Etexilate)     3/23/2016
Boehringer Ingelheim Launches Observational Study On Management Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) With Pradaxa (dabigatran etexilate mesylate)     3/23/2016
Armetheon To Participate In Two Events During Week Of J.P. Morgan Healthcare Conference     1/5/2016
Janssen Pharmaceutical Release: Real-World Data Confirms Safety And Efficacy Profile Of XARELTO, With Shorter Hospital Stays, For The Treatment Of Deep Vein Thrombosis     12/8/2015
Boehringer Ingelheim Release: FDA Approves Pradaxa (dabigatran etexilate mesylate) For Prophylaxis Of Deep Venous Thrombosis (DVT) And Pulmonary Embolism (PE) After Hip Replacement Surgery     11/23/2015
Devon Medical Products Introduces New, Portable Deep Vein Thrombosis Prevention Therapy Device     10/22/2015
Armetheon To Present At The 14th Annua BIO Investor Forum     10/14/2015
Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant To Develop Its Proteoglycan Mimetic Therapeutics To Reduce Vascular Access Failures In ESRD     8/26/2015
Bristol-Myers Squibb (BMY) And Pfizer (PFE) To Present New Data On Eliquis (apixaban) At The ESC Congress 2015     8/24/2015
Bristol-Myers Squibb Company (BMY) Release: ELIQUIS Approved For Treatment Of Venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE     11/26/2014
Bristol-Myers Squibb Company (BMY) Release: ELIQUIS Approved For Treatment Of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) And Prevention Of Recurrent DVT And PE     11/26/2014
Regado Biosciences, Inc. (RGDO)' REG2 Demonstrates Dose And Concentration-Dependent Suppression Of Thrombin Generation     6/23/2014
Portola Pharmaceuticals, Inc. Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin     6/11/2014

//-->